Perspective from Alberto Rubio Tapia, MD
Disclosures: This study was funded by Fractyl Laboratories Inc. Van Baar reports no relevant financial disclosures. Please see the full study for all other authors’ relevant financial disclosures.
February 03, 2021
1 min read
Save

Duodenal mucosal resurfacing plus liraglutide eliminates need for insulin in type 2 diabetes

Perspective from Alberto Rubio Tapia, MD
Disclosures: This study was funded by Fractyl Laboratories Inc. Van Baar reports no relevant financial disclosures. Please see the full study for all other authors’ relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Adding liraglutide and lifestyle counseling to duodenal mucosal resurfacing eliminated the need for insulin therapy in most patients with type 2 diabetes through 18 months, according to data from a feasibility study.

“[In] this feasibility study, [duodenal mucosal resurfacing (DMR)], combined with [liraglutide] and supported by lifestyle counselling, eliminated the need for insulin therapy in the majority of [type 2 diabetes] patients after 6, 12 and 18 months, while improving their glycemic and metabolic health,” Annieke C.G. van Baar, MD, PhD candidate, from the department of gastroenterology and hepatology, Amsterdam University Medical Center, Amsterdam, the Netherlands, and colleagues wrote. “Given the limited size and uncontrolled nature of this study, randomized sham-controlled studies are required to confirm its findings.”

Van Baar and colleagues’ study comprised 16 patients with insulin-treated type 2 diabetes who underwent a single duodenal mucosal resurfacing (DMR). After DMR, researchers assigned patients a 2-week postprocedural diet then they introduced the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide. The percentage of patients without insulin with an HbA1c less than 7.5% at 6 months served as the primary endpoint. Secondary endpoints included changes in multiple glycemic and metabolic parameters and percentage of responders at 12 and 18 months, respectively.

Results showed all patients underwent successful duodenal mucosal resurfacing with no procedure-related serious adverse events. Sixty-nine percent of patients were off insulin therapy and had an HbA1c of 7.5% or less at 6 months. At 12 months, 56% of patients remained off insulin, and 53% at 18 months.

According to the researchers, there were significant improvements in all patients in Homeostatic Model Assessment for Insulin Resistance, BMI, weight and liver fat fraction.

“[It] would also be interesting to observe what happens after 18 months, and to investigate whether retreatment with DMR is effective,” the investigators wrote.